ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 969,02
-0,36%
Dow Jones
38 605,07
0,09%
DAX
18 482,99
-0,68%
Brent Oil
77,115
-1,31%
Bitcoin
69 353,39
0,80%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Inhibrx Biosciences Inc (INBX)

  7. Inhibrx Biosciences Inc (INBX) Actualités

INBX

Inhibrx Biosciences (INBX)

Inhibrx Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INBX
DateHeureSourceTitreSymboleSociété
31/05/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INBXInhibrx Biosciences Inc
30/05/202422h34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:INBXInhibrx Biosciences Inc
30/05/202422h32Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:INBXInhibrx Biosciences Inc
30/05/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INBXInhibrx Biosciences Inc
28/05/202422h55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INBXInhibrx Biosciences Inc
24/05/202422h44Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INBXInhibrx Biosciences Inc
24/05/202422h00PR Newswire (US)Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiNASDAQ:INBXInhibrx Biosciences Inc
21/05/202403h48Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:INBXInhibrx Biosciences Inc
11/05/202400h36PR Newswire (US)Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffNASDAQ:INBXInhibrx Biosciences Inc
08/05/202422h37PR Newswire (US)Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerNASDAQ:INBXInhibrx Biosciences Inc
29/02/202423h26Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:INBXInhibrx Biosciences Inc
28/02/202415h15PR Newswire (US)Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:INBXInhibrx Biosciences Inc
28/02/202415h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INBXInhibrx Biosciences Inc
14/02/202422h12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INBXInhibrx Biosciences Inc
26/01/202418h12PR Newswire (US)Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law FirmNASDAQ:INBXInhibrx Biosciences Inc
23/01/202412h05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:INBXInhibrx Biosciences Inc
23/01/202411h40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:INBXInhibrx Biosciences Inc
23/01/202407h00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:INBXInhibrx Biosciences Inc
09/11/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INBXInhibrx Biosciences Inc
09/11/202322h00PR Newswire (US)Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:INBXInhibrx Biosciences Inc
02/11/202314h15PR Newswire (US)Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaNASDAQ:INBXInhibrx Biosciences Inc
18/10/202322h00PR Newswire (US)Inhibrx Announces Participation in Upcoming Scientific ConferencesNASDAQ:INBXInhibrx Biosciences Inc
19/09/202322h00PR Newswire (US)Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaNASDAQ:INBXInhibrx Biosciences Inc
31/08/202322h06Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INBXInhibrx Biosciences Inc
29/08/202315h00PR Newswire (US)Inhibrx Announces $200 Million Private Placement FinancingNASDAQ:INBXInhibrx Biosciences Inc
07/08/202322h00PR Newswire (US)Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:INBXInhibrx Biosciences Inc
30/05/202322h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
30/05/202315h46Dow Jones NewsInhibrx Granted FDA Fast Track Designation for INBRX-101NASDAQ:INBXInhibrx Biosciences Inc
30/05/202315h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
30/05/202315h00PR Newswire (US)Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyNASDAQ:INBXInhibrx Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:INBX

Dernières Valeurs Consultées

USOTC
PBSV
Pharma Bio Serv (QB)
BIT
F15600
Vontobel Financial Produ...
EU
BPCSM
BPCE 3% 19jul2026
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés